Nosocomial pulmonary infections in HIV-positive patients

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 3, 2005, Pages 231-235

  Petrosillo, Nicola ^a   Nicastri, Emanuele ^a   Viale, Pierluigi ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

AIDS; HIV; Nosocomial pulmonary infections

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; CEFTAZIDIME; COTRIMOXAZOLE; DAPSONE; ENFUVIRTIDE; PROTEINASE INHIBITOR;

ACID FAST BACTERIUM; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; BACTERIAL TRANSMISSION; CLINICAL TRIAL; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH SURVEY; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION CONTROL; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; META ANALYSIS; PATIENT COMPLIANCE; PNEUMOCYSTOSIS; PSEUDOMONAS AERUGINOSA; PUBLIC HEALTH; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; VIRUS PNEUMONIA;

EID: 17744377457     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcp.0000156993.30376.67     Document Type: Review

References (68)

1. Craven DE, Steger KA, Hirschhorn LR. Nosocomial colonization and infection in persons infected with human immunodeficiency virus. Infect Control Hosp Epidemiol 1996; 17:304-318.
2. Boumis E, Petrosillo N, Girardi E, et al. Changing patterns in the etiology of HIV-associated bacterial pneumonia in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2001; 20:71-73.
3. Paul S, Gilbert HM, Lande L, et al. Impact of antiretroviral therapy on decreasing hospitalization rates of HIV-infected patients in 2001. AIDS Res Hum Retroviruses 2002; 18:501-506.
4. Martin-Carbonero L, Soriano V, Valencia E, et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17:1467-1471.
5. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, Puoti M. Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis 2001; 33:1793-1795.
6. Goetz AM, Squier C, Wagener MM, Muder RR. Nosocomial infections in the human immunodeficiency virus-infected patient: a two-year survey. Am J Infect Control 1994; 22:334-339.
7. Weber DJ, Becherer PR, Rutala WA, et al. Nosocomial infection rate as a function of human immunodeficiency virus type 1 status in hemophiliacs. Am J Med 1991; 91:206S-212S.
8. Stroud L, Srivastava P, Culver D, et al. Nosocomial infections in HIV-infected patients: preliminary results from a multicenter surveillance system (1989-1995). Infect Control Hosp Epidemiol 1997; 18:479-485.
9. National Nosocomial Infections Surveillance System (NNISS). Semi-annual report, December 1999. Atlanta: NNISS, 1999.
10. Petrosillo N, Pugliese G, Girardi E, et al. Nosocomial infections in HIV infected patients. Gruppo HIV e Infezioni Ospedaliere. AIDS 1999; 13:599-605.
11. Daley CL, Hahn JA, Moss AR, et al. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. Am J Respir Crit Care Med 1998; 157:19-22.
12. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med 1997; 126:123-132.
13. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995; 274:143-148.
14. Ozbay B, Uzun K: Extrapulmonary tuberculosis in high prevalence of tuberculosis and low prevalence of HIV. Clin Chest Med 2002; 23:351-354.
15. Moro ML, Errante E, Infuso A, et al. Effectiveness of infection control measures in controlling a nosocomial outbreak of multidrug-resistant tuberculosis among HIV patients in Italy. Int J Tuberc Lung Dis 2000; 4:61-68.
16. Djuretic T, Herbert J, Drobniewski F, et al. Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax 2002; 57:477-482.
17. Sacks LV, Pendle S, Orlovic D, et al. A comparison of outbreak- and nonout break-related multidrug-resistant tuberculosis among human immunodeficiency virus-infected patients in a South African hospital. Clin Infect Dis 1999; 29:96-101.
18. Cobo J, Asensio A, Moreno S, et al. Risk factors for nosocomial transmission of multidrug-resistant tuberculosis due to Mycobacterium bovis among HIV-infected patients. Int J Tuberc Lung Dis 2001; 5:413-418.
19. Hannan MM, Peres H, Maltez F, et al. Investigation and control of a large outbreak of multi-drug resistant tuberculosis at a central Lisbon hospital. J Hosp Infect 2001; 47:91-97.
20. Tuberculosis outbreaks in prison housing units for HIV-infected inmates-California, 1995-1996. MMWR Morb Mortal Wkly Rep 1999; 48:79-82.
21. Drug-susceptible tuberculosis outbreak in a state correctional facility housing HIV-infected inmates-South Carolina, 1999-2000. MMWR Morb Mortal Wkly Rep 2000; 49:1041-1044.
22. Conover C, Ridzon R, Valway S, et al. Outbreak of multidrug-resistant tuberculosis at a methadone treatment program. Int J Tuberc Lung Dis 2001; 5:59-64.
23. Di Perri G, Cruciani M, Danzi MC, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989; 2:1502-1504.
24. Girardi E, Raviglione MC, Antonucci G, et al. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS 2000; 14:S47-S56.
25. Cruciani M, Malena M, Bosco O, et al. The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis. Clin Infect Dis 2001; 33:1922-1930.
26. Menzies D, Fanning A, Yuan L, Fitzgerald M: Tuberculosis among health care workers. N Engl J Med 1995; 332:92-98.
27. Di Perri G, Cadeo GP, Castelli F, et al. Transmission of HIV-associated tuberculosis to healthcare workers. Infect Control Hosp Epidemiol 1993; 14:67-72.
28. Ridzon R, Kenyon T, Luskin-Hawk R, et al. Nosocomial transmission of human immunodeficiency virus and subsequent transmission of multidrug-resistant tuberculosis in a healthcare worker. Infect Control Hosp Epidemiol 1997; 18:422-423.
29. Bennett CL, Schwartz DN, Parada JP, et al. Delays in tuberculosis isolation and suspicion among persons hospitalized with HIV-related pneumonia. Chest 2000; 117:110-116.
30. Garner JS: Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996; 17:53-80.
31. Manangan LP, Bennett CL, Tablan N, et al. Nosocomial tuberculosis prevention measures among two groups of US hospitals, 1992 to 1996. Chest 2000; 117:380-384.
32. Munoz FM, Ong LT, Seavy D, et al. Tuberculosis among adult visitors of children with suspected tuberculosis and employees at a children's hospital. Infect Control Hosp Epidemiol 2002; 23:568-572.
33. Keijman J, Tjhie J, Olde Damink S, Alink M. Unusual nosocomial transmission of Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis 2001; 20:808-809.
34. Bennett CL, Schwartz DN, Parada JP, et al. Delays in tuberculosis isolation and suspicion among persons hospitalized with HIV-related pneumonia. Chest 2000; 117:110-116.
35. Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995; 333:845-851.
36. Wallace JM, Hansen NI, Lavange L, et al. Respiratory disease trends in the Pulmonary Complications of HIV Infection Study cohort. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155:72-80.
37. Viale P, Scudeller L, Petrosillo N, et al. Clinical stability in human immunodeficiency virus-infected patients with community-acquired pneumonia. Clin Infect Dis 2004; 38:271-279.
38. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
39. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
40. Frank U, Daschner FD, Schulgen G, Mills J. Incidence and epidemiology of nosocomial infections in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 25:318-320.
41. Afessa B, Green B: Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (Pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study. Chest 2000; 118:138-145.
42. Afessa B, Green B: Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) study. Chest 2000; 117:1017-1022.
43. Tumbarello M, Tacconelli E, de Gaetano Donati K, et al. Nosocomial bacterial pneumonia in human immunodeficiency virus infected subjects: incidence, risk factors and outcome. Eur Respir J 2001; 17:636-640.
44. Baril L, Astagneau P, Nguyen J, et al. Pyogenic bacterial pneumonia in human immunodeficiency virus-infected inpatients: a clinical, radiological, microbiological, and epidemiological study. Clin Infect Dis 1998; 26:964-971.
45. Redd SC, Rutherford GW 3rd, Sande MA, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990; 162:1012-1017.
46. Meynard JL, Barbut F, Guiguet M, et al. Pseudomonas aeruginosa infection in human immunodeficiency virus infected patients. J Infect 1999; 38:176-181.
47. Manfredi R, Nanetti A, Ferri M, Chiodo F. Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey. Eur J Epidemiol 2000; 16:111-118.
48. Sorvillo F, Beall G, Turner PA, et al. Incidence and determinants of Pseudomonas aeruginosa infection among persons with HIV: association with hospital exposure. Am J Infect Control 2001; 29:79-84.
49. Takeoka K, Ichimiya T, Yamasaki T, Nasu M. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy 1998; 44:190-197.
50. Molinari G, Guzman CA, Pesce A, Schito GC. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993; 31:681-688.
51. Nicolau DP, Banevicius MA, Nightingale CH, Quintiliani R. Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model. Antimicrob Agents Chemother 1999; 43:3033-3035.
52. Viale P, Petrosillo N, Castelli F, et al. Algorithm-based management of pneumonia in HIV-1-infected patients. Lancet 2002; 359:359-360.
53. Pedro-Botet ML, Sabia M, Sopena N, et al. Legionnaires diseases and HIV infection. Chest 2003; 124:543-547.
54. Vogel P, Miller CJ, Lowenstine LL, Lackner AA. Evidence of horizontal transmission of Pneumocystis carinii pneumonia in simian immunodeficiency virus-infected rhesus macaques. J Infect Dis 1993; 168:836-843.
55. Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001; 286:2450-2460.
56. Dumoulin A, Mazars E, Seguy N, et al. Transmission of Pneumocystis carinii disease from immunocompetent contacts of infected hosts to susceptible hosts. Eur J Clin Microbiol Infect Dis 2000; 19:671-678.
57. Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol 2001; 39:3877-3882.
58. Hennequin C, Page B, Roux P, et al. Outbreak of Pneumocystis carinii pneumonia in a renal transplant unit. Eur J Clin Microbiol Infect Dis 1995; 14:122-126.
59. Cheung YF, Chan CF, Lee CW, Lau YL. An outbreak of Pneumocystis carinii pneumonia in children with malignancy. J Paediatr Child Health 1994; 30:173-175.
60. Santiago-Delpin EA, Mora E, Gonzalez ZA, et al. Factors in an outbreak of Pneumocystis carinii in a transplant unit. Transplant Proc 1988; 20:S462-S465.
61. Rabodonirina M, Vanhems P, Couray-Targeet S, et al. Molecular Evidence of Interhuman Transmission of Pneumocystis Pneumonia among Renal Transplant Recipients Hospitalized with HIV-Infected Patients. Emerg Infect Dis 2004; 10:1766-1773. Molecular typing study in a cluster of PCP in renal transplant recipient during a 3-year period. P. jirovecii organisms were typed with the multitarget polymerase chain reaction-single-strand conformation polymorphism method. Among the 45 patients with PCP hospitalized during the 3-year period, 6 HIV-infected patients may have encountered at least 1 active PCP patient within the 3 months before the diagnosis of their own PCP episode. Nosocomial interhuman transmission was hypothesized.
62. Yamada H, Kotaki H, Takahashi T. Recommendations for the treatment of fungal pneumonias. Expert Opin Pharmacother 2003; 4:1241-1258.
63. Holding KJ, Dworkin MS, Wan PC, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clin Infect Dis 2000; 31:1253-1257.
64. Darras-Joly C, Lucet JC, Laissy JP, et al. Invasive pulmonary aspergillosis in AIDS. Pathol Biol 1998; 46:416-417.
65. Chen XP, Cao Y. Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome. Clin Infect Dis 2004; 38:1030-1032. The authors observed that 0 of 19 patients with HIV infection who were hospitalized together and who had close contact with 95 patients with SARS on the same hospital floor contracted SARS, whereas 6 of 28 medical workers who served on this floor contracted SARS while caring for these patients. The authors propose that HAART should be considered for patients with SARS and their close contacts when the SARS epidemic reemerges.
66. Wong AT, Tsang OT, Wong MY, et al. Coronavirus infection in an AIDS patient. AIDS 2004; 26:829-830.
67. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59:252-256.
68. Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 2004; 318:719-725.